We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals

164 hedge funds and large institutions have $524M invested in Vanda Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 60 increasing their positions, 55 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 55

0% more funds holding

Funds holding: 164164 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 22

1.61% less ownership

Funds ownership: 101.12%99.51% (-1.6%)

17% less capital invested

Capital invested by funds: $631M → $524M (-$107M)

60% less call options, than puts

Call options by funds: $1.08M | Put options by funds: $2.69M

Holders
164
Holders Change
Holders Change %
0%
% of All Funds
3.31%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
22
Increased
60
Reduced
55
Closed
22
Calls
$1.08M
Puts
$2.69M
Net Calls
-$1.6M
Net Calls Change
+$3.36M

VNDA Hedge Fund Activity: Q3 2020 in Review

164 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2020, worth a combined $524M — down 17% from $631M a quarter earlier.

Fund positioning in VNDA was balanced in Q3 2020: 22 funds opened new positions, 22 closed out, 60 added to existing stakes and 55 trimmed.

The largest buyer was Armistice Capital, adding an estimated $6.95M. The largest seller was Invesco, cutting an estimated $15.4M.

  • 164 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2020, unchanged from Q2 2020.
  • Funds reported $524M of Vanda Pharmaceuticals stock for Q3 2020, down 17% quarter-over-quarter.
  • 22 funds opened new Vanda Pharmaceuticals positions in Q3 2020 and 22 closed out, a net change of 0 holders.
  • The largest Vanda Pharmaceuticals buyer in Q3 2020 was Armistice Capital, an estimated $6.95M added.
  • The largest Vanda Pharmaceuticals seller in Q3 2020 was Invesco, an estimated $15.4M sold.

Based on aggregated 13F filings for Q3 2020.